Özet
Major problems with the current anti-epileptic drugs (AED) are resistance, inability to modify the course of the disease and side effects profiles, which rises the need for improved AEDs for all age group of patients. Eslicarbazepine acetate is a sodium channel blocker AED and is superior to some other well-known AEDs in terms of selectivity, safety, efficacy and effects on sodium channels. In our study, to assess eslicarbazepine (S-Lic) effects, we chose wild-type Nav1.6 channels along with three SCN8A gene variants known to be causing developmental and epileptic encephalopathies (DEE), (M1760I, G1475R, and A1622D). Electrophysiological analyses were performed by using two heterologous expression systems (neuroblastoma cell line (ND7/23) for voltage-clamp recordings, and primary neuronal cultures for current-clamp recordings). 300 μM of S-Lic reduced maximal firing rates in neurons having wild-type NaV1.6 channels. S-Lic enhanced slow inactivation kinetics in all DEE variants tested, but also displayed variant-specific effects by modifying biophysical properties of tested variant channels. S-Lic treatment increased the kinetics of fast inactivation and reduced the persistent current in A1622D variant. Additionally, S-Lic decreased neuronal firing rate to that of wild-type in M1760I variant. Those findings emphasize the significance of individualized therapy, and prompt the potential use of Eslicarbazepine acetate, -taking into account its unique effects on epileptogenesis and slow inactivation, and its better safety and therapeutic index – as an alternative option against some SCN8A (NaV1.6) variants causing DEE.
Künye
1. Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family. Genome Biol. 2003;4(3):207.
2. Chen K, Godfrey DA, Ilyas O, Xu J, Preston TW. Cerebellum-related characteristics of Scn8a-mutant mice. Cerebellum. 2009;8(3):192-201.
3. Chahine M, O'Leary ME. Regulatory Role of Voltage-Gated Na Channel beta Subunits in Sensory Neurons. Front Pharmacol. 2011;2:70.
4. Meisler MH, O'Brien JE, Sharkey LM. Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects. J Physiol. 2010;588(Pt 11):1841-8.
5. Gertler TS, Carvill GL. SCN8A: When Neurons Are So Excited, They Just Can't Hide It. Epilepsy Curr. 2019;19(4):269-71.
6. Gardella E, Moller RS. Phenotypic and genetic spectrum of SCN8A-related disorders, treatment options, and outcomes. Epilepsia. 2019;60 Suppl 3:S77-S85.
7. Bunton-Stasyshyn RKA, Wagnon JL, Wengert ER, Barker BS, Faulkner A, Wagley PK, et al. Prominent role of forebrain excitatory neurons in SCN8A encephalopathy. Brain. 2019;142(2):362-75.
8. Lerche H. New hope for the treatment of epilepsy. Brain. 2015;138(Pt 2):240-2.
9. Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, et al. Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review. Pharmacol Rev. 2016;68(3):563-602.
10. Mula M. Recent and future antiepileptic drugs and their impact on cognition: what can we expect? Expert Rev Neurother. 2012;12(6):667-71.
11. Nadkarni S, Devinsky O. Psychotropic effects of antiepileptic drugs. Epilepsy Curr. 2005;5(5):176-81.
12. Billakota S, Devinsky O, Kim KW. Why we urgently need improved epilepsy therapies for adult patients. Neuropharmacology. 2019:107855.
13. Pressler RM, Lagae L. Why we urgently need improved seizure and epilepsy therapies for children and neonates. Neuropharmacology. 2019:107854.
14. Wang J, Ou SW, Wang YJ. Distribution and function of voltage-gated sodium channels in the nervous system. Channels (Austin). 2017;11(6):534-54.
15. Brunklaus A, Lal D. Sodium channel epilepsies and neurodevelopmental disorders: from disease mechanisms to clinical application. Dev Med Child Neurol. 2020.
16. Li ZM, Chen LX, Li H. Voltage-gated Sodium Channels and Blockers: An Overview and Where Will They Go? Curr Med Sci. 2019;39(6):863-73.
17. Huang W, Liu M, Yan SF, Yan N. Structure-based assessment of disease-related mutations in human voltage-gated sodium channels. Protein Cell. 2017;8(6):401-38.
18. Xu L, Ding X, Wang T, Mou S, Sun H, Hou T. Voltage-gated sodium channels: structures, functions, and molecular modeling. Drug Discov Today. 2019;24(7):1389-97.
19. Wood JN, Iseppon F. Sodium channels. Brain Neurosci Adv. 2018;2:2398212818810684.
20. Kwong K, Carr MJ. Voltage-gated sodium channels. Curr Opin Pharmacol. 2015;22:131-9.
21. Namadurai S, Yereddi NR, Cusdin FS, Huang CL, Chirgadze DY, Jackson AP. A new look at sodium channel beta subunits. Open Biol. 2015;5(1):140192.
22. Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189-205.
23. Katz E, Stoler O, Scheller A, Khrapunsky Y, Goebbels S, Kirchhoff F, et al. Role of sodium channel subtype in action potential generation by neocortical pyramidal neurons. Proc Natl Acad Sci U S A. 2018;115(30):E7184-E92.
24. Meisler MH, Plummer NW, Burgess DL, Buchner DA, Sprunger LK. Allelic mutations of the sodium channel SCN8A reveal multiple cellular and physiological functions. Genetica. 2004;122(1):37-45.
25. Goldin AL. Evolution of voltage-gated Na(+) channels. J Exp Biol. 2002;205(Pt 5):575-84.
26. O'Brien JE, Meisler MH. Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability. Front Genet. 2013;4:213.
27. Stafstrom CE. Persistent sodium current and its role in epilepsy. Epilepsy Curr. 2007;7(1):15-22.
28. Cannon SC, Bean BP. Sodium channels gone wild: resurgent current from neuronal and muscle channelopathies. J Clin Invest. 2010;120(1):80-3.
29. Veeramah KR, O'Brien JE, Meisler MH, Cheng X, Dib-Hajj SD, Waxman SG, et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet. 2012;90(3):502-10.
30. Steward CA, Roovers J, Suner MM, Gonzalez JM, Uszczynska-Ratajczak B, Pervouchine D, et al. Re-annotation of 191 developmental and epileptic encephalopathy-associated genes unmasks de novo variants in SCN1A. NPJ Genom Med. 2019;4:31.
31. El Kosseifi C, Cornet MC, Cilio MR. Neonatal Developmental and Epileptic Encephalopathies. Semin Pediatr Neurol. 2019;32:100770.
32. Scheffer IE, Liao J. Deciphering the concepts behind "Epileptic encephalopathy" and "Developmental and epileptic encephalopathy". Eur J Paediatr Neurol. 2020;24:11-4.
33. Musto E, Gardella E, Moller RS. Recent advances in treatment of epilepsy-related sodium channelopathies. Eur J Paediatr Neurol. 2020;24:123-8.
34. Gardella E, Marini C, Trivisano M, Fitzgerald MP, Alber M, Howell KB, et al. The phenotype of SCN8A developmental and epileptic encephalopathy. Neurology. 2018;91(12):e1112-e24.
35. Wagnon JL, Meisler MH. Recurrent and Non-Recurrent Mutations of SCN8A in Epileptic Encephalopathy. Front Neurol. 2015;6:104.
36. Schwarz N, Hahn A, Bast T, Muller S, Loffler H, Maljevic S, et al. Mutations in the sodium channel gene SCN2A cause neonatal epilepsy with late-onset episodic ataxia. J Neurol. 2016;263(2):334-43.
37. Butler KM, da Silva C, Shafir Y, Weisfeld-Adams JD, Alexander JJ, Hegde M, et al. De novo and inherited SCN8A epilepsy mutations detected by gene panel analysis. Epilepsy Res. 2017;129:17-25.
38. Larsen J, Carvill GL, Gardella E, Kluger G, Schmiedel G, Barisic N, et al. The phenotypic spectrum of SCN8A encephalopathy. Neurology. 2015;84(5):480-9.
39. Liu Y, Schubert J, Sonnenberg L, Helbig KL, Hoei-Hansen CE, Koko M, et al. Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability. Brain. 2019;142(2):376-90.
40. Parrini E, Marini C, Mei D, Galuppi A, Cellini E, Pucatti D, et al. Diagnostic Targeted Resequencing in 349 Patients with Drug-Resistant Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes. Hum Mutat. 2017;38(2):216-25.
41. Wang J, Gao H, Bao X, Zhang Q, Li J, Wei L, et al. SCN8A mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures. BMC Med Genet. 2017;18(1):104.
42. Xiao Y, Xiong J, Mao D, Liu L, Li J, Li X, et al. Early-onset epileptic encephalopathy with de novo SCN8A mutation. Epilepsy Res. 2018;139:9-13.
43. Zaman T, Abou Tayoun A, Goldberg EM. A single-center SCN8A-related epilepsy cohort: clinical, genetic, and physiologic characterization. Ann Clin Transl Neurol. 2019;6(8):1445-55.
44. Zuliani V, Rapalli A, Patel MK, Rivara M. Sodium channel blockers: a patent review (2010 - 2014). Expert Opin Ther Pat. 2015;25(3):279-90.
45. Vohora D, Saraogi P, Yazdani MA, Bhowmik M, Khanam R, Pillai KK. Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. Drugs Today (Barc). 2010;46(4):265-77.
46. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5(7):553-64.
47. Dilena R, Striano P, Gennaro E, Bassi L, Olivotto S, Tadini L, et al. Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy. Brain Dev. 2017;39(4):345-8.
48. Moller RS, Johannesen KM. Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers. Neurotherapeutics. 2016;13(1):190-1.
49. Ijff DM, Aldenkamp AP. Chapter 73 - Cognitive side-effects of antiepileptic drugs in children. In: Dulac O, Lassonde M, Sarnat HB, editors. Handbook of Clinical Neurology. 111: Elsevier; 2013. p. 707-18.
50. Hessen E, Lossius MI, Reinvang I, Gjerstad L. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia. 2006;47(12):2038-45.
51. Watkins L, O'Dwyer M, Oak K, Lawthom C, Maguire M, Thomas R, et al. The evidence for switching dibenzazepines in people with epilepsy. Acta Neurol Scand. 2020.
52. Fricke-Galindo I, A LL, Jung-Cook H, Lopez-Lopez M. Carbamazepine adverse drug reactions. Expert Rev Clin Pharmacol. 2018;11(7):705-18.
53. Helbig I, Ellis CA. Personalized medicine in genetic epilepsies - possibilities, challenges, and new frontiers. Neuropharmacology. 2020;172:107970.
54. Zuliani V, Fantini M, Rivara M. Sodium channel blockers as therapeutic target for treating epilepsy: recent updates. Curr Top Med Chem. 2012;12(9):962-70.
55. Stevens M, Peigneur S, Tytgat J. Neurotoxins and their binding areas on voltage-gated sodium channels. Front Pharmacol. 2011;2:71.
56. Benarroch EE. Sodium channels and pain. Neurology. 2007;68(3):233-6.
57. Lattanzi S, Brigo F, Cagnetti C, Verrotti A, Zaccara G, Silvestrini M. Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy. Core Evid. 2018;13:21-31.
58. Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935-46.
59. Willems LM, Zollner JP, Paule E, Schubert-Bast S, Rosenow F, Strzelczyk A. Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence. Expert Rev Clin Pharmacol. 2018;11(3):309-24.
60. Galiana GL, Gauthier AC, Mattson RH. Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures. Drugs R D. 2017;17(3):329-39.
61. Singh RP, Asconape JJ. A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy. J Cent Nerv Syst Dis. 2011;3:179-87.
62. Elger C, Bialer M, Falcao A, Vaz-da-Silva M, Nunes T, Almeida L, et al. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia. 2013;54(8):1453-61.
63. Almeida L, Falcao A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol. 2005;45(9):1062-6.
64. Falcao A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. CNS Drugs. 2012;26(1):79-91.
65. Soares-da-Silva P, Pires N, Bonifacio MJ, Loureiro AI, Palma N, Wright LC. Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. Pharmacol Res Perspect. 2015;3(2):e00124.
66. Doeser A, Dickhof G, Reitze M, Uebachs M, Schaub C, Pires NM, et al. Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. Brain. 2015;138(Pt 2):371-87.
67. Shorvon SD, Trinka E, Steinhoff BJ, Holtkamp M, Villanueva V, Peltola J, et al. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies. J Neurol. 2017;264(3):421-31.
68. Assenza G, Mecarelli O, Lanzone J, Assenza F, Tombini M, Di Lazzaro V, et al. The ROME (Retrospective Observational Multicenter study on Eslicarbazepine) study: Efficacy and behavioural effects of Eslicarbazepine acetate as adjunctive therapy for adults with partial onset seizures in real life. Seizure. 2018;58:35-40.
69. Jozwiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P. Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures. Epilepsy Behav. 2018;81:1-11.
70. Klein P, Friedman A, Hameed MQ, Kaminski RM, Bar-Klein G, Klitgaard H, et al. Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? Epilepsia. 2020;61(3):359-86.
71. Pitkanen A, Lukasiuk K, Dudek FE, Staley KJ. Epileptogenesis. Cold Spring Harb Perspect Med. 2015;5(10).
72. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77(1):51-9.
73. Reikofski J, Tao BY. Polymerase chain reaction (PCR) techniques for site-directed mutagenesis. Biotechnol Adv. 1992;10(4):535-47.
74. Wood JN, Bevan SJ, Coote PR, Dunn PM, Harmar A, Hogan P, et al. Novel cell lines display properties of nociceptive sensory neurons. Proc Biol Sci. 1990;241(1302):187-94.
75. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A. 1987;84(21):7413-7.
76. Hedrich UB, Liautard C, Kirschenbaum D, Pofahl M, Lavigne J, Liu Y, et al. Impaired action potential initiation in GABAergic interneurons causes hyperexcitable networks in an epileptic mouse model carrying a human Na(V)1.1 mutation. J Neurosci. 2014;34(45):14874-89.
77. Beaudoin GM, 3rd, Lee SH, Singh D, Yuan Y, Ng YG, Reichardt LF, et al. Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat Protoc. 2012;7(9):1741-54.
78. Moutin E, Hemonnot AL, Seube V, Linck N, Rassendren F, Perroy J, et al. Procedures for Culturing and Genetically Manipulating Murine Hippocampal Postnatal Neurons. Front Synaptic Neurosci. 2020;12:19.
79. Bean BP. The action potential in mammalian central neurons. Nat Rev Neurosci. 2007;8(6):451-65.
80. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol. 1952;117(4):500-44.
81. Cole KS, Moore JW. Potassium ion current in the squid giant axon: dynamic characteristic. Biophys J. 1960;1:1-14.
82. Neher E, Sakmann B. Single-channel currents recorded from membrane of denervated frog muscle fibres. Nature. 1976;260(5554):799-802.
83. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391(2):85-100.
84. Liem LK, Simard JM, Song Y, Tewari K. The patch clamp technique. Neurosurgery. 1995;36(2):382-92.
85. Bebarova M. Advances in patch clamp technique: towards higher quality and quantity. Gen Physiol Biophys. 2012;31(2):131-40.
86. Rubaiy HN. A Short Guide to Electrophysiology and Ion Channels. J Pharm Pharm Sci. 2017;20:48-67.
87. Brown AP, Greenberg HZ. Patch clamp. Br J Hosp Med (Lond). 2016;77(5):C74-7.
88. Kornreich BG. The patch clamp technique: principles and technical considerations. J Vet Cardiol. 2007;9(1):25-37.
89. Liao Y, Deprez L, Maljevic S, Pitsch J, Claes L, Hristova D, et al. Molecular correlates of age-dependent seizures in an inherited neonatal-infantile epilepsy. Brain. 2010;133(Pt 5):1403-14.
90. Erofeev A, Gerasimov E, Lavrova A, Bolshakova A, Postnikov E, Bezprozvanny I, et al. Light Stimulation Parameters Determine Neuron Dynamic Characteristics. Applied Sciences. 2019;9(18).
91. Alekov AK, Peter W, Mitrovic N, Lehmann-Horn F, Lerche H. Two mutations in the IV/S4-S5 segment of the human skeletal muscle Na+ channel disrupt fast and enhance slow inactivation. Neurosci Lett. 2001;306(3):173-6.
92. Kole MH, Stuart GJ. Is action potential threshold lowest in the axon? Nat Neurosci. 2008;11(11):1253-5.
93. Hebeisen S, Pires N, Loureiro AI, Bonifacio MJ, Palma N, Whyment A, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015;89:122-35.
94. Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia. 2001;42(5):600-8.
95. Doeser A, Soares-da-Silva P, Beck H, Uebachs M. The effects of eslicarbazepine on persistent Na(+) current and the role of the Na(+) channel beta subunits. Epilepsy Res. 2014;108(2):202-11.
96. Holtkamp D, Opitz T, Hebeisen S, Soares-da-Silva P, Beck H. Effects of eslicarbazepine on slow inactivation processes of sodium channels in dentate gyrus granule cells. Epilepsia. 2018;59(8):1492-506.
97. Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neurosci Lett. 2018;667:27-39.
